Mathilde/NLI4PR huggingface dataset:
Patient case (clinical description): A 47-year-old man comes to the clinic for the follow up of his neuromuscular disease. He experienced gradual, progressive weakness of the left upper extremity over the last year.  Over the last few months, he has also noticed weakness in the right upper extremity.  BP is 120/75, PR is 80 and temperature is 37 C. Reflexes are brisk in the upper extremities, and the plantar responses are extensor.  Mild gait ataxia is present. The patient is under treatment of Riluzole 50 mg BID with the diagnosis of ALS.

Patient's own account: I've been suffering from a neuromuscular disease for a while now, and I went to my doctor's office. I'm now a 47-year-old man and over the past year I experienced a progressive and gradual weakness of my left upper extremity, and over the past month, I also noticed a weakness over my right upper extremity. My heart rate was 120/75, and my  PR was 80 with 37°C for temperature. My reflexes are not good in my upper extremities, and I have trouble with my balance. I'm also under Exservan 50 mg for my sclerosis.

Clinical trial: Phase 3 Study of Dexpramipexole in ALS

Eligibility criteria:
Inclusion Criteria:

          -  Aged 18 to 80 years old, inclusive, on Day 1.

          -  Diagnosis of sporadic or familial ALS.

          -  Onset of first ALS symptoms within 24 months prior to Day 1.

          -  World Federation of Neurology El Escorial criteria are met for a possible,
             laboratory-supported probable, probable, or definite ALS diagnosis.

          -  Upright slow vital capacity (SVC) of 65% or more at screening.

          -  Patients taking or not taking Riluzole are eligible for this study: if a patient has
             never taken Riluzole, he or she is eligible; if a patient is currently taking
             Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient
             has discontinued Riluzole, he or she must have stopped taking it for at least 30 days.

          -  Must be able to swallow tablets at the time of study entry.

        Exclusion Criteria:

          -  Other medically significant illness.

          -  Clinically significant abnormal laboratory values.

          -  Pregnant women or women breastfeeding.

          -  Prior exposure to dexpramipexole.

          -  Currently taking pramipexole or other dopamine agonists.

        Other protocol-defined inclusion/exclusion criteria may apply.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 80 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Eligibility criteria:
Inclusion Criteria:

          -  Male and female patients of any age and ethnicity

          -  Severe haemophilia A (FVIII:C<1%)

          -  Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study

          -  Either

          -  No previous treatment with FVIII concentrates or other blood products containing FVIII
             (PUPs) OR

          -  Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood products
             containing FVIII (MTPs), if

          -  their first ED occurred after 1st January 2015, AND

          -  they did not develop an inhibitor at any time point, OR

          -  they developed an inhibitor during treatment with an Octapharma FVIII concentrate AND
             continue treatment with THIS Octapharma FVIII concentrate

          -  Voluntarily given, fully informed written and signed consent obtained before any
             study-related data documentation is conducted (obtained from the patient's
             parent/legal guardian)

        Exclusion Criteria:

          -  Diagnosis with a coagulation disorder other than haemophilia A

          -  Concomitant treatment with any systemic immunosuppressive drug

          -  Participation in an interventional clinical trial during the time period evaluated

          -  Participation in another non-interventional study of Octapharma
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Contradiction
Patient case (clinical description): A 20-year-old man comes to the clinic for his routine checkup. The patient wears glasses for myopia and takes no medications.  Vital signs are normal.  On physical examination, the patient is tall with long upper extremities and fingers.  The face appears narrow with down-slanted palpebral fissures, flattened malar bones, and a small jaw.  The lungs are clear on auscultation.  The abdomen is soft with no organomegaly. The patient is diagnosed with Marfan syndrome, and he is cooperative with his medical appointments. He is working as driver.

Patient's own account: I'm a 20-year-old guy, working as a driver and I went to the clinic for my routine checkup. I have myopia, so I wear glasses and I don't take any other medications. My vitals were normal. I also did a physical exam, and I was told that I have long legs, arms, and fingers. They also told me that my face is quite narrow, with down-slanted eyes and a small jaw. My lungs were fine and my tummy too. I have been diagnosed with Marfan syndrome and I haven't been skipping any medical appointments since.

Clinical trial: Marfan Syndrome Moderate Exercise Pilot

Eligibility criteria:
Inclusion Criteria:

          -  Must be between the ages of 12-21

          -  Diagnosis of Marfan Syndrome

          -  Must not have other conditions that limit the patients ability to perform exercise

        Exclusion Criteria:

          -  Patients who have undergone aortic surgery

          -  Patients with major congenital heart disease
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 12 Years old.
Subject must be at most 21 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 15-year-old boy with mild intellectual disability is brought to the office by his parents for a routine physical examination.  The boy is going to a school for students with learning disabilities.  The patient was adopted, and his immunizations are up to date.  Review of the patient's medical records is notable for cytogenetic studies that showed a small gap near the tip of the long arm of the X chromosome, which is consistent with fragile X syndrome, an X-linked disorder. The defect is an unstable expansion of trinucleotide repeats (CGG) in the fragile X mental retardation 1 (FMR1) gene, located on the long arm of the X chromosome. He is not using any medications and vital signs are within normal levels. His blood chemistry analysis as bellow:
Blood Chemistry Value      Normal Range     Patient Value
Glucose                    90-120 mg/dl     95 mg/dl
BUN (Blood Urea Nitrogen)  7-24 mg/dl       10 mg/dl
Creatinine                 0.7-1.4 mg/dl    0.8 mg/dl
Calcium                    8.5-10.5 mg/dl   9 mg/dl
Sodium                     134-143 mEq/L    135 mEq/L
Potassium                  3.5-4.5 mEq/L    3.7 mEq/L
Chloride                   95-108 mEq/L     98 mEq/L
CO2                        20-30 mEq/L      25 mEq/L
Blood pH                   7.38-7.42        7. 39

Patient's own account: My husband and I brought our 15-year-old son to the clinic for his routine exam. My son is going to school for special needs students. We adopted him a few years ago. His vaccinations are up to date. He already passed some chromosome testing and they found that he has a fragile X syndrome. The doctor told us that it comes from repeats in the fragile X chromosome. My son is not using any medication and his blood pressure temperature and breathing were normal during the exam. He also did a blood test. The results came back and showed that his blood sugar urea creatinine calcium sodium potassium chloride CO2 and blood pH were all within the normal range.

Clinical trial: North Health in Intellectual Disability

Eligibility criteria:
Inclusion Criteria:

          -  Clinical diagnosis of intellectual disability

          -  Age 16 or older and providing consent to participate.

        Exclusion Criteria:

        -
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 16 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient's own account: I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Clinical trial: Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI

Eligibility criteria:
Inclusion Criteria:

          -  Women undergoing ICSI with expected poor ovarian response according to the Bologna
             criteria

        Exclusion Criteria:

          -  Body mass index >35 Kg/m2.

          -  Women with a single ovary.

          -  Allergy to DHEA or GH.

          -  Diabetic women on insulin as insulin lowers DHEA levels and might reduce its
             effectiveness
Female
No healthy subjects accepted to join the trial.
Subject must be at least 20 Years old.
Subject must be at most 43 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 48-year-old man comes to the office complaining of heartburn and acid reflux.  He has taken over-the-counter antacids but sees no relief.  Other medical history is unremarkable.  The patient does not use tobacco, alcohol, or illicit drugs.  Vital signs are within normal limits.  BMI is 31 kg/m2.  Physical examination is  positive for mild tenderness in upper stomach. Chest x-ray shows an air-fluid opacity behind the heart.  A barium swallow study reveals approximately 1/3 of the stomach herniating through the esophageal hiatus.

Patient's own account: I went to my doctor's office because of a non-stop heartburn and some acid reflux. I took over-the-counter medications, but it keeps going strong! I don't smoke, take drugs or drink alcohol, I'm healthy! The doctor took my vitals, which turned out normal. My BMI is 31, which might be a bit too much for a 48-year-old guy like me. They examined my stomach and found a mild tenderness in the upper part. I also did some X-rays, and they found out that I have an air-fluid opacity behind my heart. I did another X-ray, and it turns out that a part of my stomach went up my chest through a hole in my diaphragm!

Clinical trial: Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Eligibility criteria:
Inclusion Criteria:

          1. Subject who has signed on the written consent

          2. Male and female aged 20 and over

          3. Endoscopically verified Reflux Esophagitis classified into Los Angeles classification
             Grade A, B, C or D within 2 weeks before randomisation

        Exclusion Criteria:

          1. History or presence of upper gastrointestinal anatomic or motor disorders

          2. Other exclusions apply.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 20 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): An 8-year-old boy is brought to the clinic by his parents because of weakness and difficulty of standing up from a sitting position. The mother is healthy but had a brother who died in his 20th after being disabled and using wheelchairs in the last few years of his life. Physical examination shows 3/5 lower extremity muscle strength and enlarged calf muscles. The other physical examination and vital signs are unremarkable. Muscle biopsy showed absence of dystrophin protein. The patient is diagnosed with DMD.

Patient's own account: I brought my  8-year-old son to the doctor's clinic. He was struggling to stand up from a chair for the past few days. My wife is healthy but she was pretty worried since his brother died in his 20s after being disabled and using a wheelchair for the last years of his life. The doctor did an exam which highlighted weakness in the leg muscles and unusually large calf muscles. The rest of the exam was fine, and his vitals were normal. My son did a muscle biopsy, and it showed that the protein important for muscle strength and function is missing. The doctor diagnosed him with Duchenne muscular dystrophy.

Clinical trial: Encouraging Physical Activity: Action Or Direction?

Eligibility criteria:
Inclusion Criteria:

          -  Being between the ages of 9-14

          -  Being literate in Turkish

          -  Not having any physical disability preventing them from doing physical activities

          -  Attending physical education class regularly

        Exclusion Criteria:

          -  Having a serious cognitive impairment

          -  Going to school on foot

          -  Physiotherapists to be selected for the physiotherapist group to work in the field of
             sports
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 9 Years old.
Subject must be at most 14 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 40-year-old woman comes to the clinic complaining of gritty sensation in her eyes. She also has difficulty swallowing dry foods with no pain or heartburn.  The patient is a schoolteacher and must drink water frequently during lectures due to her mouth dryness.  She also reports occasional joint pain.  Medical history is not significant other than the confirmed Sjogren disease with no other rheumatologic disease.  She is sexually active with her husband and has 2 children both delivered by natural vaginal delivery. She has no history of any kind of surgery. Physical examination shows conjunctival erythema and cracking of the lips. The remainder of the examination and history is normal. Her lab result shows elevated ESR (50 mm/h)

Patient's own account: I went to the clinic because I had a terrible gritty sensation in my eyes. It was also hard to swallow dry food, but it didn't burn, and there was no pain. I'm a 40-year-old female school teacher and I should drink water for the lectures because otherwise, my mouth gets really dry. I also have joint pain from time to time. I have been diagnosed with Sjogren disease but no other rheumatologic disease. I have a husband, we're sexually active, and I also have two lovely children that I delivered both naturally. I never undergone any surgery. Physical examination when I came to the clinic, and it showed cracking on my lips and a pink eye. The rest was fine. I also did some lab tests, and they came back with high ESR.

Clinical trial: Etanercept Therapy for Sjogren's Syndrome

Eligibility criteria:
INCLUSION CRITERIA

        Documented primary or secondary SS.

        Absence of confounding health problems.

        No contraindications to etanercept therapy.

        SS patients cannot have sarcoidosis, HIV infection, or lymphoma.

        Patients must have one of the following abnormal autoimmune serologies associated with SS
        (i.e. positive ANA, RF, and anti-SS-A, or anti-SS-B).

        Patients may use pilocarpine provided that they hold their dose on visit days when saliva
        is collected.

        Patients taking DMARD's, such as hydroxychloroquine, must be on a stable dose.

        Participants may take NSAIDs or acetaminophen.

        EXCLUSION CRITERIA

        Patients must not have physical or mental conditions that may make them unable to comply.

        Subjects may continue their other long-term medications with the exception of tricyclic
        antidepressants and anti-cholinergics, which may affect salivary gland function.

        Patients cannot take experimental drugs during the duration of the protocol.

        Children will be excluded due to additional risks that may occur with etanercept.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Entailment
Patient case (clinical description): A 47-year-old woman comes to the office complaining of pain in the calf and knee when she bends down. The pain limits her activity. Her medical history is significant for osteoarthritis, for which she uses nonsteroidal anti-inflammatory drugs (NSAIDs) for the past two years. She is living with her husband and has 3 children. She doesn't smoke but drinks alcohol occasionally. Her vital signs are normal. On physical examination, there is a small effusion in the right knee. The effusion grew a little larger and she developed a tender swelling in the popliteal fossa and calf. Both the pain and swelling worsened as she bent and straightened her knee.

Patient's own account: I'm a 47-year-old woman, married with 3 kids. I don't smoke and I drink occasionally. I went to the doctor because of pain in my calf and knee when I was bending down. This has been limiting my daily activities. I have been diagnosed with osteoarthritis for which I have taken anti-inflammatory drugs for the past 2 years. The doctor saw a small fluid buildup in my right knee. This buildup became a bit bigger and I have a swollen calf. The pain is worse when I bend and straighten my knee.

Clinical trial: Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis

Eligibility criteria:
Inclusion Criteria:

        Inclusion Criteria for OA patients:

          -  Fulfilling the American College of Rheumatology (ACR) criteria for the diagnosis of
             knee osteoarthritis

          -  Symptomatic knee pain

          -  On usual care for knee osteoarthritis including paracetamol and/or NSAIDs

        Inclusion criteria for Inflammatory Arthritis Patients:

          -  Fulfilling the American College of Rheumatology (ACR) criteria for the diagnosis of
             inflammatory arthritis i.e. rheumatoid arthritis (Anti-CCP antibodies & Rheumatoid
             Factor checked ), psoriatic arthritis or spondyloarthropathy

          -  Symptomatic knee pain

          -  On usual care for arthritis including disease-modifying anti-rheumatic drugs (DMARDs),
             paracetamol and/or NSAIDs

        Exclusion Criteria:

          -  Other rheumatological diagnosis e.g. systemic lupus erythematosus, fibromyalgia,
             Polymyalgia Rheumatica, Gout, Giant Cell Arteritis, Sjogren's syndrome

          -  History of uncontrolled depression

          -  Recent surgery

          -  Uncontrolled ischaemic heart disease

          -  Uncontrolled diabetes mellitus

          -  Alcohol consumption > 14 units/week as per UK National guidelines

          -  Participants unable to give full informed consent
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 67-year-old man comes to the clinic with slowly worsening vision in both eyes.  He is not able to drive at night, as the symptoms are worse at night. His pupils are normal in diameter both in the light and darkness. Other medical history is unremarkable.  Ocular examination shows loss of the red reflex and blurry vision.  Acuity testing shows 50/100 vision in both eyes with normal visual field testing. His blood pressure is 130/70 and pulse is 68/min. the other physical examinations are normal.

Patient's own account: I am a 67 years-old man, and I haven't been able to drive at night due to my vision getting worse. My vision is not the best in general, but night makes it even worse. The ophthalmologist told me that my pupils were normal. However, I have slow reflexes and blurry vision. My acuity test came back with 50/100 vision in both of my eyes. They also took my blood pressure, which was 130/70 with a 68 pulse. My other exams came back just fine.

Clinical trial: Lutein for Age-Related Macular Degeneration

Eligibility criteria:
INCLUSION CRITERIA:

        Men and women aged 60 years or older.

        Patients ranging from no AMD with little or no drusen in either eye through end stage AMD
        (geographic atrophic, retinal pigment epithelial detachment, or other signs of
        neovascular/exudative disease) in their eye with worst disease will be eligible.

        The ability to understand and sign an informed consent form prior to enrollment.

        EXCLUSION CRITERIA:

        Ocular disease which confounds assessment of the retina other than age-related macular
        degeneration including diabetic retinopathy, central serous choroidopathy, optic atrophy,
        retinal vein occlusion, active uveitis, significant explained or unexplained visual field
        loss, or any other type of retinopathy or retinal degeneration.

        Chronic requirement for any systemic or ocular medication for other diseases such as
        glaucoma.

        Patients has regularly been taking lutein supplements during the last 3 months or is
        currently taking lutein supplements. The daily use of the new Centrum or Centrum Silver or
        other similar multivitamins will be allowed but should be limited to a maximum of twice a
        day.

        Abnormal liver function tests.

        Inability to be followed for a period of 1 year.

        Acute potentially life-threatening illness such as heart attack in the last year, malignant
        cancer or blood disease not in remission.

        History of lung cancer.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Entailment